Ther Innov Regul Sci
Review of Drugs Approved via the 505(b)(2) Pathway: Uncovering Drug Development Trends and Regulatory Requirements.
Freije I, Lamouche S, Tanguay M
A 505(b)(2) application is a type of US new drug application (NDA) that contains full reports of investigations of safety and effectiveness, but where ...
Read More
Source: PubMed
Intensive Care Med 2020 Jan 30
Intraosseous versus intravenous administration of adrenaline in patients with out-of-hospital cardiac arrest: a secondary analysis of the PARAMEDIC2 placebo-controlled trial.
Nolan JP, Deakin CD, Ji C, Gates S, Rosser A, Lall R, Perkins GD
To compare the effectiveness of the intravenous (IV) and intraosseous (IO) routes for drug administration in adults with a cardiac arrest enrolled in ...
Read More
Source: PubMed
Bioorg. Med. Chem. 2020 Jan 20
A panoramic review of IL-6: Structure, pathophysiological roles and inhibitors.
Kaur S, Bansal Y, Kumar R, Bansal G
Interleukin-6 (IL-6) is a pleiotropic pro-inflammatory cytokine. Its deregulation is associated with chronic inflammation, and multifactorial auto-imm ...
Read More
Source: PubMed
Pharmaceutics
Targeting Small Molecule Delivery to the Brain and Spinal Cord via Intranasal Administration of Rabies Virus Glycoprotein (RVG29)-Modified PLGA Nanoparticles.
Chung EP, Cotter JD, Prakapenka AV, Cook RL, DiPerna DM, Sirianni RW
Alternative routes of administration are one approach that could be used to bypass the blood-brain barrier (BBB) for effective drug delivery to the ce ...
Read More
Source: PubMed
Mol. Ther. 2020 Jan 13
Muscle-Directed Delivery of an AAV1 Vector Leads to Capsid-Specific T Cell Exhaustion in Nonhuman Primates and Humans.
Gernoux G, Gruntman AM, Blackwood M, Zieger M, Flotte TR, Mueller C
With the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) approvals for Zolgensma, Luxturna, and Glybera, recombinant adeno-a ...
Read More
Source: PubMed
